Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP6 | P55212 | 1/20 | 0.32 |
| ▸ | ADH1B | P00325 | 2/20 | 0.31 |
| ▸ | ADH1C | P00326 | 2/20 | 0.31 |
| ▸ | ADH1A | P07327 | 2/20 | 0.31 |
| ▸ | ADH7 | P40394 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | ADH4 | P08319 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17533431 | 0.79 | — | — | |
| SCHEMBL9323765 | 0.77 | GSR (0.36) | CASP6POLBGAA | |
| SCHEMBL12241917 | 0.77 | — | — | |
| SCHEMBL12241916 | 0.75 | — | — | |
| SCHEMBL11805003 | 0.72 | — | — | |
| SCHEMBL11804996 | 0.72 | — | — | |
| SCHEMBL14610674 | 0.72 | — | — | |
| SCHEMBL918192 | 0.71 | ADH1A (0.38) | ADH1BADH1CADH1AADH7ADH4 | |
| SCHEMBL16256831 | 0.71 | ADH1A (0.38) | ADH1BADH1CADH1AADH7ADH4 | |
| SCHEMBL918191 | 0.71 | ADH1A (0.38) | ADH1BADH1CADH1AADH7ADH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2649062-B1 | BICYCLIC COMPOUNDS AS INHIBITORS OF ACETYL-COA CARBOXYLASE (ACC) | TAKEDA PHARMACEUTICAL (JP) | 2015-04-08 | — | — | EP | disclosed |
| US-8729102-B2 | Bicyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-05-20 | — | — | US | disclosed |
| US-8703758-B2 | Bicyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-04-22 | — | — | US | disclosed |
| US-20120142714-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-06-07 | — | — | US | disclosed |
| US-20120142714-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-06-07 | — | — | US | disclosed |
| WO-2012074126-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-06-07 | — | — | WO | disclosed |
| US-20110263562-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-10-27 | — | — | US | disclosed |
| US-20110263562-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263562-A1 | BICYCLIC COMPOUND | ACACA, CPT1B, ACACB | CASP6 2989/4885ADH1B 1918/4885ADH1C 427/4885 |
| US-20120142714-A1 | BICYCLIC COMPOUND | ACACA, ACACB, FABP4 | CASP6 1974/4885ADH1B 838/4885ADH1C 231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.